Seeking Alpha

AVI BioPharma (AVII +1.5%) says an independent data safety monitoring board has found no safety...

AVI BioPharma (AVII +1.5%) says an independent data safety monitoring board has found no safety concerns for its Phase IIb study of eteplirsen in Duchenne Muscular Dystrophy patients. The board has now given the go signal for the company to proceed with the trial as planned.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)